• Sulaikha S
  • sreejith koorikat kerala University of Health sciences
  • Nadiya Banu M T
  • Shabana Thehsin k
  • Arshida p
  • Midhun K P


Commonly available therapeutic approaches for treating anemia of chronic kidney disease include oral iron supplementation such as ferrous fumarate, intra venous iron administration and erythropoiesis stimulating agents including erythropoietin, darbepoetin alfa, etc. Nowadays ESAs are used widely to treat anemia of chronic kidney disease and several studies have found that if used inappropriately it can even lead to cardiovascular diseases. The harmful effect of free iron in human body includes microbial growth promotion and free radical-induced reactions which can further cause deterioration of patient condition. Iron overload can lead to organ multiple organ failure in kidney disease patients. The iron level in the body is one of the significant factor for the effectiveness of erythropoietin. A well maintained iron homeostasis is required in the kidney disease patients to observe an effective treatment for anemia in chronic kidney disease patients. Lactoferrin, an iron-binding glycoprotein has been studied widely for its effect on iron homeostasis, anti-microbial activity, etc. Its safety and efficacy over other oral iron supplements have been established from several studies. This review article aims to support the need for further studies for attaining more vast knowledge regarding the use of lactoferrin in the treatment of anemia of chronic kidney disease.

 Keywords: Anemia in chronic kidney disease, free iron, erythropoiesis stimulating agents (ESA), Lactoferrin, Glycoprotein, Iron homeostasis



Download data is not yet available.

Author Biography

sreejith koorikat, kerala University of Health sciences

Assistant Professor

Department of Pharmacy Practice

College of pharmaceutical sciences

Government Medical college

 Kozhikode, Kerala, India



1. Kumar V, Abbas AK, Fausto N, Aster JC. Robbins and Cotran pathologic basis of disease.
2. Reddy GC, Devaki R, Rao P. Iron indices in patients with functional anemia in chronic kidney disease. EJIFCC. 2014 Feb;24(3):129.
3. Theurl I, Aigner E, Theurl M, Nairz M, Seifert M, Schroll A, Sonnweber T, Eberwein L, Witcher DR, Murphy AT, Wroblewski VJ. Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications. Blood. 2009 May 21;113(21):5277-86.
4. Goddard AF, James MW, McIntyre AS, Scott BB. Guidelines for the management of iron deficiency anaemia. Gut. 2011 Oct 1;60(10):1309-16.
5. Breymann C, Honegger C, Holzgreve W, Surbek D. Diagnosis and treatment of iron-deficiency anaemia during pregnancy and postpartum. Archives of gynecology and obstetrics. 2010 Nov 1;282(5):577-80.
6. Ward PP, Paz E, Conneely OM. Lactoferrin. Cellular and molecular life sciences. 2005 Nov 1;62(22):2540.
7. Ziere GJ, Van Dijk MC, Bijsterbosch MK, van Berkel TJ. Lactoferrin uptake by the rat liver. Characterization of the recognition site and effect of selective modification of arginine residues. Journal of Biological Chemistry. 1992 Jun 5;267(16):11229-35.
8. McAbee DD, Esbensen K. Binding and endocytosis of apo-and holo-lactoferrin by isolated rat hepatocytes. Journal of Biological Chemistry. 1991 Dec 15;266(35):23624-31.
9. Peen E, Johansson A, Engquist M, Skogh T. Hepatic and extrahepatic clearance of circulating human lactoferrin: an experimental study in rat. European journal of haematology. 1998 Sep;61(3):151-9.
10. Peen E, Eneström S, Skogh T. Distribution of lactoferrin and 60/65 kDa heat shock protein in normal and inflamed human intestine and liver. Gut. 1996 Jan 1;38(1):135-40.
11. Beljaars L, Bakker HI, van der Strate BW, Smit C, Duijvestijn AM, Meijer DK, Molema G. The antiviral protein human lactoferrin is distributed in the body to cytomegalovirus (CMV) infection-prone cells and tissues. Pharmaceutical research. 2002 Jan 1;19(1):54-62.
12. Yao X, Bunt C, Cornish J, Quek SY, Wen J. Oral delivery of lactoferrin: a review. International Journal of Peptide Research and Therapeutics. 2013 Jun 1;19(2):125-34.
13. Valenti P, Vogel HJ. Lactoferrin, all roads lead to Rome. Biometals. 2014 Oct 1;27(5):803-6.
14. Masson PL, Heremans JF, Schonne E. Lactoferrin, an iron-binbing protein Ni neutrophilic leukocytes. Journal of Experimental Medicine. 1969 Sep 1;130(3):643-58.
15. Kawakami H, Hiratsuka M, Dosako SI. Effects of iron-saturated lactoferrin on iron absorption. Agricultural and biological chemistry. 1988 Apr 1;52(4):903-8.
16. Koikawa N, Nagaoka I, Yamaguchi M, Hamano H, Yamauchi K, Sawaki K. Preventive effect of lactoferrin intake on anemia in female long distance runners. Bioscience, biotechnology, and biochemistry. 2008 Apr 23;72(4):931-5.
17. Nappi C, Tommaselli GA, Morra I, Massaro M, Formisano C, Di Carlo C. Efficacy and tolerability of oral bovine lactoferrin compared to ferrous sulfate in pregnant women with iron deficiency anemia: a prospective controlled randomized study. Actaobstetricia et gynecologica Scandinavica. 2009 Jan 1;88(9):1031-5.
18. Paesano R, Berlutti F, Pietropaoli M, Goolsbee W, Pacifici E, Valenti P. Lactoferrin efficacy versus ferrous sulfate in curing iron disorders in pregnant and non-pregnant women. International journal of immunopathology and pharmacology. 2010 Apr; 23(2):577-87.
19. Paesano R, Berlutti F, Pietropaoli M, Pantanella F, Pacifici E, Goolsbee W, Valenti P. Lactoferrin efficacy versus ferrous sulfate in curing iron deficiency and iron deficiency anemia in pregnant women. Biometals. 2010 Jun 1; 23(3):411-7.
20. Paesano R, Pacifici E, Benedetti S, Berlutti F, Frioni A, Polimeni A, Valenti P. Safety and efficacy of lactoferrin versus ferrous sulphate in curing iron deficiency and iron deficiency anaemia in hereditary thrombophilia pregnant women: an interventional study. Biometals. 2014 Oct 1;27(5):999-1006.
21. Paesano R, Pietropaoli M, Gessani S, Valenti P. The influence of lactoferrin, orally administered, on systemic iron homeostasis in pregnant women suffering of iron deficiency and iron deficiency anaemia. Biochimie. 2009 Jan 1;91(1):44-51.
22. Rezk M, Kandil M, Dawood R, Shaheen AE, Allam A. Oral lactoferrin versus ferrous sulphate and ferrous fumerate for the treatment of iron deficiency anemia during pregnancy. Journal of Advanced Nutrition and Human Metabolism. 2015 Apr 7;1.
23. Rezk M, Dawood R, Abo-Elnasr M, Al Halaby A, Marawan H. Lactoferrin versus ferrous sulphate for the treatment of iron deficiency anemia during pregnancy: a randomized clinical trial. The Journal of Maternal-Fetal& Neonatal Medicine. 2016 May 2;29(9):1387-90.
24. Cash JM, Sears DA. The anemia of chronic disease: spectrum of associated diseases in a series of unselected hospitalized patients. The American journal of medicine. 1989 Dec 1;87(6):638-44.
25. Mehedintu C, Ionescu OM, Ionescu S, Cirstoiu MM, Dumitrascu MC, Bratila E, Dumitrescu R, Oprescu DN, Tataru CP, VladareanuS. Iron deficiency and iron-deficiency anaemia in pregnant women corrected by oral bovine lactoferrin administration.Farmacia. 2015 Nov 1;63:922-6.
26. Hashim HA, Foda O, Ghayaty E. Lactoferrin or ferrous salts for iron deficiency anemia in pregnancy: A meta-analysis of randomized trials. European Journal of Obstetrics &Gynecology and Reproductive Biology. 2017 Dec 1;219:45-52.
27. Kopelman RC et al. Functional iron deficiency in hemodialysis patients with high ferritin. Hemodialysis International. 2007 Apr;11(2):238-46.
915 Views | 455 Downloads
How to Cite
S S, koorikat sreejith, M T NB, k ST, p A, K P M. LACTOFERRIN, A PROMISING MOLECULE FOR THE TREATMENT OF ANEMIA OF CHRONIC KIDNEY DISEASE. JDDT [Internet]. 15Aug.2019 [cited 19Jan.2022];9(4-s):610-2. Available from:

Most read articles by the same author(s)